Sugi Predict

Sugi Predict / Compounds / SCHEMBL4375689

SCHEMBL4375689

SCHEMBL4375689

[CH2]C1CCN(CCCC2CCNC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GNAO1 P09471 6/20 0.45
▸ GNAI3 P08754 5/20 0.41
▸ GNAI1 P63096 5/20 0.41
▸ CXCR4 P61073 2/20 0.37
▸ SLC6A1 P30531 2/20 0.33
▸ GABRA5 P31644 2/20 0.33
▸ GABRB2 P47870 2/20 0.33
▸ SLC6A12 P48065 2/20 0.33
▸ SLC6A11 P48066 2/20 0.33
▸ SLC6A13 Q9NSD5 2/20 0.33
▸ GABRA1 P14867 1/20 0.33
▸ GABRR1 P24046 1/20 0.33
▸ GABRA4 P48169 1/20 0.33
▸ NAAA Q02083 1/20 0.31
▸ ITGB3 P05106 2/20 0.31
▸ ITGA2B P08514 2/20 0.31
▸ TPSAB1 Q15661 1/20 0.30
▸ TPSD1 Q9BZJ3 1/20 0.30
▸ TPSG1 Q9NRR2 1/20 0.30
▸ HRH3 Q9Y5N1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4378119 0.90 CXCR4 (0.41) GNAO1GNAI3GNAI1CXCR4NAAA
SCHEMBL4374852 0.88 GNAO1 (0.38) GNAO1GNAI3GNAI1CXCR4
SCHEMBL4664558 0.85 GNAO1 (0.48) GNAO1GNAI3GNAI1CXCR4SLC6A1
SCHEMBL3395893 0.84 CXCR4 (0.50) GNAO1GNAI3GNAI1CXCR4SLC6A1
SCHEMBL4373301 0.82 GNAO1 (0.48) GNAO1GNAI3GNAI1CXCR4SLC6A1
SCHEMBL4664115 0.81 GNAO1 (0.50) GNAO1GNAI3GNAI1CXCR4SLC6A1
SCHEMBL2750958 0.80 GNAO1 (0.42) GNAO1GNAI3GNAI1CXCR4SLC6A1
SCHEMBL4157945 0.79 GNAO1 (0.47) GNAO1GNAI3GNAI1CXCR4SLC6A1
SCHEMBL28250746 0.79 SLC6A1 (0.37) GNAO1SLC6A1GABRA5GABRB2SLC6A12
SCHEMBL21025824 0.77 GNAO1 (0.44) GNAO1GNAI3GNAI1CXCR4SLC6A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 — — US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 — — US disclosed
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 — — EP disclosed
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity HENNEQUIN LAURENT FRANCOIS ANDRE 2008-12-18 — — US disclosed
US-7371765-B2 Quinoline derivatives having VEGF inhibiting activity ASTRAZENECA AB (SE) 2008-05-13 — — US disclosed
US-7262201-B1 For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals ASTRAZENECA AB (SE) 2007-08-28 — — US disclosed
US-7074800-B1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2006-07-11 — — US disclosed
US-20060148819-A1 Chemical compounds HENNEQUIN LAURENT F A 2006-07-06 — — US disclosed
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB 2006-01-05 — — US disclosed
EP-1553097-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE AstraZeneca AB (SE) 2005-07-13 — — EP disclosed
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity ASTRAZENECA AB (SE) 2003-10-23 — — US disclosed
EP-1313726-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY AstraZeneca AB (SE) 2003-05-28 — — EP disclosed
EP-1311500-A2 INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY AstraZeneca AB (SE) 2003-05-21 — — EP disclosed
EP-1309587-A1 CINNOLINE COMPOUNDS AstraZeneca AB (SE) 2003-05-14 — — EP disclosed
WO-2002016348-A1 ANTIANGIOGENIC BICYCLIC DERIVATIVES ASTRAZENECA AB (SE) 2002-02-28 — — WO disclosed
WO-2002012228-A1 CINNOLINE COMPOUNDS ASTRAZENECA AB (SE) 2002-02-14 — — WO disclosed
WO-2002012227-A2 INDOLE, AZAINDOLE AND INDAZOLE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 — — WO disclosed
WO-2002012226-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 — — WO disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 — — EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity VEGFA, FLT1, FLT4 GNAO1 1728/4885GNAI3 1107/4885GNAI1 920/4885
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR GNAO1 1723/4885GNAI3 376/4885GNAI1 278/4885
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity VEGFA, FLT1, FLT4 GNAO1 187/4885GNAI3 58/4885GNAI1 31/4885
US-20060148819-A1 Chemical compounds VEGFA, NOS3, FLT4 GNAO1 1348/4885GNAI3 1444/4885GNAI1 2250/4885
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors FLT4, NOS3, FLT1 GNAO1 860/4885GNAI3 1371/4885GNAI1 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.